Jubilant Life Sciences's subsidiary Jubiliant Pharma issues unsecured bonds for USD 200 mn

Image
Capital Market
Last Updated : Mar 01 2019 | 10:04 AM IST
Jubilant Life Sciences announced that its wholly-owned subsidiary, Jubilant Pharma has successfully priced its rated unsecured bonds (the 'Notes') at 6.00% per annum issued at par for US$200 million maturing in March, 2024.

S&P Global Ratings ('S&P') has affirmed BB-/positive rating and Fitch Ratings ('Fitch') has affirmed BB-/Stable rating for JPL (the issuer of the Notes). The Notes have been rated BB- by S&P and BB by Fitch.

The major portion of the net proceeds of the Notes shall be used to refinance existing indebtedness and pay associated fees and premiums over a period of time and the balance amount for working capital and general corporate purposes

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 01 2019 | 9:39 AM IST

Next Story